Genting New Yao announced that Ellacycline (XERAVA) has been approved in Hong Kong for the treatment of complicated intra-abdominal infections in adults

Shanghai, October 8, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.
HK), a biopharmaceutical company focused on the development and commercialization of innovative medicines dedicated to meeting the unmet medical needs of the Asian market, today announced that the Department of Health of the Hong Kong Special Administrative Region of China has approved the marketing authorization application for the new antimicrobial drug Ilacycline (XERAVA^®) in Hong Kong, China.
For the treatment of complicated intra-abdominal infection (cIAI)
in adults.

Zhu Xu, Chief Medical Officer of Genting Xinyao in the field of infectious diseases, said: "The approval of the listing of elocycline in Hong Kong, China marks another important milestone for Genting Xinyao, which fulfills our commitment to benefit
patients with limited treatment options.
Complicated intra-abdominal infection in adults is still the leading bacterial infectious disease in the clinic, and the increasing number of infections associated with multidrug-resistant bacteria has become an increasingly serious public health problem
.
We are pleased that this new drug approval will provide patients and physicians in Hong Kong, China with innovative options for treating severe infectious diseases, and we look forward to bringing this important therapy to Chinese mainland and other parts
of Asia as soon as possible.
" "

Through an licensing agreement with Tetraphase Pharmaceuticals, a wholly-owned subsidiary of La Jolla Pharmaceuticals, Genting Sunnyau enjoys an exclusive interest
in the development and commercialization of irocycline in Greater China, South Korea and select key markets in Southeast Asia, including Indonesia, Malaysia, the Philippines, Thailand, Singapore and Vietnam.
In April 2020, irocycline was approved in Singapore for the treatment of complicated intra-abdominal infections in adults, and applications for marketing authorization for drugs in Chinese mainland and Taiwan are pending
.

Since 2020, ellacycline has been recommended as a treatment regimen
for multidrug-resistant gram-negative infections including carbapenem-resistant by multiple drug-resistant gram-negative infections published by the American Society of Infectious Diseases (IDSA) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID).
At the same time, the drug has also been included in the "Expert Consensus on Multidisciplinary Diagnosis and Treatment of Common Abdominal Infections in Surgery" jointly issued by the Surgery Branch of the Chinese Medical Association and the Professional Committee of Evidence-Based and Translational Infectious
Diseases of the Chinese Research Hospital Association.

About Ellacycline (XERAVA^®)

Ellacycline (XERAVA^®) is a new, fully synthesized, broad-spectrum, fluorotetracycline-contained, intravenous antimicrobial drug used for the treatment of first-line empirical monotherapy
for multidrug-resistant infections including gram-negative and gram-positive infections common in China.
Hiralcycline is currently approved in the United States, the European Union, the United Kingdom, and Singapore for the treatment of complicated intra-abdominal infection
in adults.
Genting New Yao is also developing indications
for the treatment of community-acquired bacterial pneumonia.
Ellacycline is an authorized introduction
by Genting Xinyao from Tetraphase Pharmaceuticals, a wholly owned subsidiary of La Jolla Pharmaceuticals.
For more information, please click at:

About complicated intra-abdominal infection

Complicated intra-abdominal infection (cIAI) is a nosocomial or community-acquired infection that causes peritonitis or abscesses that extend from a cavity to the peritoneal cavity
.
cIAI includes abdominal abscess, gastric or intestinal perforation, peritonitis, appendicitis, cholecystitis, diverticulitis, etc
.
cIAI is caused by different pathogens, including gram-negative, gram-positive, and anaerobic bacteria
.
In 2018, about 2.
9 million cIAI patients Chinese mainland, and the rising rate of infections due to drug-resistant bacteria limits the effectiveness
of existing antimicrobial use.

About Genting New Shine

Genting New Yao is a biopharmaceutical company focused on the development and commercialization of innovative drugs, dedicated to meeting the unmet medical needs
of the Asian market.
Genting Sunny's management team has deep expertise and extensive experience in high-quality clinical development, pharmaceutical affairs, chemical manufacturing and control (CMC), business development and operations in leading pharmaceutical companies in China and around the
world.
Genting New Yao has created a number of drug combinations that have the potential to become the world's first or best-of-breed drug combinations, most of which are already in the late stages
of clinical development.
The company's therapeutic areas include tumors, autoimmune diseases, cardiorenal diseases, infectious and infectious diseases
.
For more information, visit the company website: www.
everestmedicines.
com

Forward-Looking Statements:

The information published in this press release may contain certain forward-looking statements based on the Company's or management's existing views, beliefs, and existing expectations of the Company's business operations and financial condition at the time of the statement, and may be expressed using words such as "will," "expect," "forecast," "expect," "intend," "plan," "believe," "estimate," "assert" and other similar words
.
These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and other factors, some of which are beyond the control of the Company and are difficult to predict
.
As a result, actual results may differ materially from
those contained in forward-looking statements due to various factors and assumptions such as future changes and developments in our business, competitive environment, political, economic, legal and social circumstances.
The Company and its affiliates, directors, officers, advisors and agents have not and undertake no obligation to update the forward-looking statements contained in this press release to reflect the latest information, future projects or circumstances following the date of this press release, except as required
by law.